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FK 506 Versus Cyclosporine 
T.E. Starzl 
I will be asking which drug is the most potent. least toxic. 
easiest to administer. and most compatible with other 
drugs for combination therapy. Both drugs are enormously 
versatile and can be used with all of the established 
immunosuppressants. induding steroids and the antilym-
phoid preparations. The discovery of the spectacular syn-
ergism between FK 506 and old or new antimetabolite 
drugs has opened the immediate possibilities of xenotrans-
plantation. l 
Because both FK 506 and cyclosporine (CyA) are me-
tabolized by the liver. there is a particular risk of overdos-
age in patients with hepatic dysfunction. resulting in astro-
nomical blood levet(s) in FK 506-treated patients whose 
liver grafts do not function weU.2 This phenomenon has 
been more completely studied with FK 5063 and may be 
more extreme. but it also occurs with CyA. 
The ease of administration nod may go to FK 506. Its 
oral absorption is not dependent upon bile. making adjust-
ments or overlapping of intravenous and oral dosage 
unnecessary with bile fistulas or other abnormalities of 
biliary drainage. Also in contrast to CyA. FK 506 is so 
little affected by malabsorption and diarrhea that the doses 
and blood levels are not much different after intestinal 
grafting than after any other kind of whole-organ trans-
plantation. 4 
The relative toxicities of FK 506 vs CyA were accu-
rately summarized in San Francisco 2 years ago (Table I), 
The nephrotoxicity. neurotoxicity, and diabetogenicity of 
the two drugs were thought then (and still are) to be 
comparable and strictly dose related. There are differ-
ences. Hypertension and hypercholesterolemia are less 
with FK 506. Gingival hyperplasia. hirsutism, and the 
coursening of features evident with Cy A do not occur with 
Table 1. Nonlmmunologlc Profile (4 + Wont) (All Dose Related) 
Nephrotoxicity 
Neurotoxicity 
DlabetogenlCity 
Growth effects 
Hirsutism 
Gingival hyperplasia 
F adal brutilization 
Hepatotrophic effects 
Gynecomastia 
Other metabolic effects 
Cholesterol increase 
Uric acid increase 
Reprinted with permission.2 
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Fig 1. Survival after liver transplantation in azathioprine. CyA. 
and FK 506 eras. During the azathioprine era (lower line). patient 
and graft survival were synonymous. The middle band (CyA) and 
upper band (FK 506) have patient survival as the upper border and 
graft survival as the lower border. 
FK 506. This is slightly puzzling because FK 506 is at least 
as potent as CyA in promoting certain kinds of growth. 
such as hepatic regeneration. and in preventing the hepa-
tocyte atrophy caused in experimental models by Eck 
fistula. 
These so-called hepatotrophic or "liver-healing" prop-
erties of both drugsS could help explain why they had such 
an extraordinary effect on the prognosis after liver trans-
plantation (Fig 1). In a Pittsburgh randomized trial of FK 
506 vs Cy A, the liver transplant and recipient survival 
curves in the FK 506 and CyA arms were not significantly 
different when analyzed by intent to treat. However. in 
this trial. a crossover was permitted based on physician 
judgment that a patient had rejection that could not be 
controlled at all or could not be controlled without the 
excessive use of steroids. This resulted in a flight from 
CyA to the extent that more than half of the recipients 
started on the Cy A limb were switched to FK 506 within 6 
months. The crossover phenomenon could have reflected 
a bias on the part of the physicians allowing the crossover. 
However. a more important explanation came from the 
quality of life studies (physical. psychological, and social 
well-being) of Simmons in heart6 as well as liver recipients. 
In all 16 indices measured. the FK 506 patients had better 
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scores and in most of these, the differences were statisti-
cally significant. 
This doctor-initiated. as well as patient-driven crossover 
phenomena seen with the liver. also affected the kidney 
randomized trials in that about 20% of the patients started 
on CyA ended up with good results by virtue of FK 506 
rescue as reported in another session at this meeting by 
Jordan. These observations caused an abandonment of 
these trials more than a year ago. As in the liver studies. it 
was proved that patient and graft survival curves based on 
intent to treat could be made equal. providing crossover 
rescue was aUowed. 
Since then. double versus triple-drug FK 506-based 
protocols have been evaluated in cadaver kidney recipi-
ents. all comers--primary and retransplantation-the im-
munologically difficult retransplant cohort being 32% of 
the total. Patient survival has been 99% (one death in 125 
cases). Graft survival in recipients treated with FK 506 and 
prednisone (double drug) have fared the same as those 
treated with the triple-drug combination of FK 506. pred-
nisone. and azathioprine (85% I-year graft survival). These 
trials are presented in detail elsewhere at this congress. 
In our heart program. I-year graft and patient survival 
has been approximately 90%. As with the other organs. the 
ability to quickly reduce or stop steroids has been a 
particular advantage in children. There has been no evi-
dence of the coronary arteritis reported by Morris in rats. 
Leaving aside the debating rhetoric. a new drug stands 
or falls by allowing (or failing to allow) accomplishments 
that were not attainable before. FK 506 has been a tool on 
both sides of the Atlantic with which a large number of 
patients who have failed treatment with CyA have been 
rescued. The ability to cross over in the randomized trials 
admittedly has blurred the distinction between Cy A and 
FK 506. but it has helped the patients and has allowed us 
--------
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to succeed more often today than was possible 3Vz years 
ago. 
To move on. we can point today to a collection of 
patients whom I thought I might not see in my lifetime: 
recipients of complete cadaveric small bowel. either trans-
planted alone. with the liver. or as part of a multivisceral 
graft. 4 Another sight that I thought I might never see is that 
of a well recipient of a baboon liver. This was accom-
plished in June under the same FK 506-based cocktail as 
we use routinely for liver allotransplantation with the 
addition of nontoxic doses of cyclophosphamide. This 
patient. who died after 70 days without experiencing 
serious rejection. is reported elsewhere. 
What has emerged from the actual testing of FK 506 is a 
step up the ladder of progress that has already been taken. 
Perhaps that has placed the value of FK 506 beyond the 
boundary of a debatable issue. In fact. FK 506 and Cy A 
are both great drugs that have changed the face of medi-
cine. Debating their fate is uncomfortably like determining 
which of fraternal twins should be allowed to live. Perhaps 
we will conclude "Why not both?" 
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